Drug intelligence / Profile preview

ΦK-8 + ΦDΔ + ΦEΔ

Development stage
Preclinical
Lead developer
The Chinese University of Hong Kong
Modality
Live Biotherapeutic Products → Microbiome Therapeutics
01

Overview

ΦK-8 + ΦDΔ + ΦEΔ is a rationally designed three-phage combination (phage cocktail) developed by researchers at The Chinese University of Hong Kong. It consists of three novel lytic bacteriophages isolated from wastewater: ΦK-8 (belonging to the Casjensviridae family, χ-like), ΦDΔ (belonging to the Demerecviridae family, T5-like), and ΦEΔ (belonging to the Straboviridae family, T4-like). The cocktail is designed to target and control clinical high-risk carbapenem-resistant Klebsiella pneumoniae (CRKP) sequence type 307 (ST307) isolates. By combining these three phages, the cocktail exploits complementary resistance trade-offs and creates an evolutionary trap, where ΦK-8 kills mutants adapted to ΦDΔ/ΦEΔ, and ΦDΔ/ΦEΔ eliminates ΦK-8-resistant mutants, thereby achieving sustained bacterial killing and suppressing the rapid emergence of phage resistance.

Other names
phiK-8 + phiDDelta + phiEDeltaphiK-8 + phiDDelta + phiEDelta phage cocktailthree-phage combination (ΦK-8 + ΦDΔ + ΦEΔ)ΦK-8 + ΦDΔ + ΦEΔ phage cocktail
02

Targets

FepA (Ferric enterobactin receptor FepA)K1 CPS (Klebsiella pneumoniae capsular polysaccharide serotype K1)LPS (Lipopolysaccharide)OmpK36 (Outer membrane porin OmpK36)

Beyond the preview

Go deeper on ΦK-8 + ΦDΔ + ΦEΔ.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ΦK-8 + ΦDΔ + ΦEΔ.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call